Filing Details
- Accession Number:
- 0001209191-18-063382
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-12-18 21:46:18
- Reporting Period:
- 2018-12-14
- Accepted Time:
- 2018-12-18 21:46:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1370053 | Anaptysbio Inc | ANAB | Pharmaceutical Preparations (2834) | 203828755 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1654495 | Hamza Suria | C/O Anaptysbio, Inc. 10421 Pacific Center Court, Suite 200 San Diego CA 92121 | President, Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-12-14 | 41,728 | $1.12 | 71,792 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-12-14 | 24,844 | $68.89 | 46,948 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-12-14 | 9,084 | $69.68 | 37,864 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-12-14 | 7,800 | $70.51 | 30,064 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2018-12-14 | 41,728 | $0.00 | 41,728 | $1.12 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 129,284 | 2022-01-31 | No | 4 | M | Direct |
Footnotes
- The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.31 to $69.30 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.31 to $70.30 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.33 to $70.98 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The stock option is fully vested and immediately exercisable.
- In addition to the remaining options to purchase 129,284 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 705,554 shares of common stock, which options vest according to their terms, and (ii) 30,064 shares of common stock held directly.
Billionaire Hedge Funds
